The term "Personalized medicine" is used quite loosely; it basically refers to the use of genetics or other biomarker data to guide patient treatment decisions. These decisions I involve determining which patients should receive particular medicines or quantities of a given drug, or which patients should be given closer monitoring because they are more likely to experience a certain safety risk. The study of genetic variants and their impact on how individuals respond to pharmaceuticals has been referred to as genetics, pharmacogenetics, personalised medicine, and pharmacogenomics. Let's look at how we now treat patients to better appreciate the potential of pharmacogenomics. In the event that you visit the practitioner for high blood pressure, for instance, he or she may likely prescribe you any of a variety of blood pressure drugs based on very little knowledge of what will be effective for you. In fact, you might not even have a good reason for receiving that particular prescription other than the fact because your coverage supports it or because the doctor has some samples on hand. If the prescription doesn't start working after 4 to 6 weeks, it can be changed, or another medication might be given on base of the first.
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian FederationSubmit your abstract Today
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Emerging formulation and delivery applications of Vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia